Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05870397
Other study ID # 2023-0184
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 21, 2023
Est. completion date August 21, 2024

Study information

Verified date April 2023
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Yuehua Han, MD
Phone +86057189713734
Email 13858126927@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Although Urea breath test has been commonly used to recheck the efficiency of Helicobacter pylori eradication, there has been no randomized trials comparing the accuracy of Urea breath test results at different times after eradication. The investigators aim to assess the accuracy and influence factors of post-therapy test at different times and follow up the cut off samples to optimize the best time to recheck.


Description:

The investigators plan to conduct a single-center, open-label, randomized controlled study in Zhejiang, China. Treatment-naive H. pylori-positive participants (n = 900) were randomly assigned to three groups in a 1:1:1 ratio with the same eradication regimen: amoxicillin 1000 mg, clarithromycin 500mg, rabeprazole 10mg, and colloidal bismuth 200 mg each given twice a day for 14 days. Urea breath tests were administered at different times after the treatment: 4 to 6 weeks, 6 to 8 weeks, and 8 to 10 weeks, respectively, for different groups.


Recruitment information / eligibility

Status Recruiting
Enrollment 900
Est. completion date August 21, 2024
Est. primary completion date April 21, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - no history of helicobacter pylori treatment - the diagnosis of H. pylori infection was confirmed by one or more of the following methodologies before treatment: gastric biopsy using histochemical staining, tissue culture, the 14C-urea breath test (UBT), and/or the 13C-UBT. Exclusion Criteria: - used antibiotics or bismuth within four weeks before inclusion or acid inhibitor use, including H2 receptor antagonist (H2RA), PPI or P-CAB use, within two weeks prior to inclusion. - had an active peptic ulcer with complications such as hemorrhage, perforation, or obstruction. - had a history of esophagectomy or gastrectomy. - had an allergy to any study drug. - had severe comorbidities or physical or mental diseases. - were pregnant or breastfeeding. - had a history of alcohol abuse or drug addiction.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times
Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.

Locations

Country Name City State
China 2nd Affilicated Hosptal,School of Medicine,Zhejiang University,China Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the eradication rate in each group (ITT analysis) According to the breath urea test, calculation the eradication rate in the three groups. ITT analysis, the number of negative breath test cases after treatment divided by the number of cases enrolled in eradication therapy. up to 4 months after eradication therapy
Primary the eradication rate in each group (PP analysis) According to the breath urea test, calculation the eradication rate in the three groups. PP analysis, the number of negative breath test cases after treatment divided by the number of cases finished the eradication therapy up to 4 months after eradication therapy
Secondary follow up of cut off cases If the result of breath urea test is betwwen 2 to 6, it will be defined as cut off value. These cases will be collected and take further tests to make sure the real situation of helicobacter pylori infection. up to 4 months after eradication therapy.
See also
  Status Clinical Trial Phase
Completed NCT02873065 - Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori Phase 4
Recruiting NCT06349486 - Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication N/A
Completed NCT03924375 - Serum Pepsinogen After H. Pylori Eradication
Recruiting NCT04034641 - Effect of Probiotics on Helicobacter Pylori Eradication Phase 4
Completed NCT04850209 - The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori N/A
Not yet recruiting NCT04558502 - Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication Phase 4
Completed NCT06101420 - Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication Phase 3
Recruiting NCT06088316 - Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT Phase 4
Recruiting NCT05850117 - Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p N/A
Recruiting NCT05191888 - 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy Phase 4